Nomura Asset Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$350M Buy
380,578
+11,546
+3% +$11.7M 0.9% 13
2025
Q4
$397M Buy
369,032
+16,212
+5% +$15.5M 1% 11
2025
Q3
$269M Sell
352,820
-7,434
-2% -$5.53M 0.7% 14
2025
Q2
$281M Sell
360,254
-3,940
-1% -$3.06M 0.77% 16
2025
Q1
$301M Buy
364,194
+11,574
+3% +$9.63M 0.92% 13
2024
Q4
$272M Buy
352,620
+9,034
+3% +$7.48M 0.82% 13
2024
Q3
$304M Buy
343,586
+11,273
+3% +$10.1M 0.94% 12
2024
Q2
$301M Sell
332,313
-55,536
-14% -$44.4M 1.03% 13
2024
Q1
$302M Buy
387,849
+7,666
+2% +$5.46M 1.1% 11
2023
Q4
$222M Buy
380,183
+21,755
+6% +$12.7M 0.92% 12
2023
Q3
$193M Sell
358,428
-44,138
-11% -$22.7M 0.9% 14
2023
Q2
$189M Buy
402,566
+15,966
+4% +$6.7M 0.87% 13
2023
Q1
$133M Buy
386,600
+50,439
+15% +$17M 0.7% 23
2022
Q4
$123M Buy
336,161
+40,902
+14% +$14.5M 0.71% 24
2022
Q3
$95.5M Sell
295,259
-41,804
-12% -$13.2M 0.61% 29
2022
Q2
$109M Buy
337,063
+26,149
+8% +$7.85M 0.68% 22
2022
Q1
$89M Sell
310,914
-63,519
-17% -$16.3M 0.48% 38
2021
Q4
$103M Buy
374,433
+99,393
+36% +$25.2M 0.52% 30
2021
Q3
$63.5M Buy
275,040
+1,505
+0.6% +$371K 0.36% 66
2021
Q2
$62.8M Buy
273,535
+11,791
+5% +$2.37M 0.36% 64
2021
Q1
$48.9M Sell
261,744
-4,964
-2% -$971K 0.31% 79
2020
Q4
$45M Buy
266,708
+14,251
+6% +$2.13M 0.3% 78
2020
Q3
$37.4M Buy
252,457
+63,503
+34% +$9.83M 0.29% 83
2020
Q2
$31M Sell
188,954
-11,344
-6% -$1.74M 0.26% 85
2020
Q1
$27.8M Buy
200,298
+4,943
+3% +$679K 0.29% 76
2019
Q4
$25.7M Sell
195,355
-21,526
-10% -$2.5M 0.23% 93
2019
Q3
$24.3M Buy
216,881
+18,773
+9% +$2.09M 0.23% 98
2019
Q2
$21.9M Sell
198,108
-3,829
-2% -$451K 0.22% 96
2019
Q1
$26.2M Sell
201,937
-304,807
-60% -$37.1M 0.26% 87
2018
Q4
$58.6M Buy
506,744
+22,169
+5% +$2.48M 0.66% 31
2018
Q3
$52M Sell
484,575
-259,951
-35% -$26M 0.5% 45
2018
Q2
$63.5M Sell
744,526
-25,300
-3% -$2.08M 0.66% 36
2018
Q1
$59.6M Buy
769,826
+9,766
+1% +$786K 0.65% 34
2017
Q4
$64.2M Buy
760,060
+148,955
+24% +$12.7M 0.74% 31
2017
Q3
$52.3M Buy
611,105
+58,011
+10% +$4.76M 0.68% 35
2017
Q2
$45.5M Buy
553,094
+21,771
+4% +$1.78M 0.61% 34
2017
Q1
$44.7M Buy
531,323
+305,068
+135% +$24.4M 0.63% 34
2016
Q4
$16.6M Buy
226,255
+16,568
+8% +$1.23M 0.3% 85
2016
Q3
$16.8M Buy
209,687
+4,309
+2% +$345K 0.3% 80
2016
Q2
$16.2M Buy
205,378
+34,989
+21% +$2.63M 0.3% 81
2016
Q1
$12.3M Buy
170,389
+24,667
+17% +$1.87M 0.23% 112
2015
Q4
$12.3M Buy
145,722
+2,252
+2% +$187K 0.24% 114
2015
Q3
$12M Buy
143,470
+1,840
+1% +$155K 0.24% 111
2015
Q2
$11.8M Sell
141,630
-4,540
-3% -$346K 0.22% 121
2015
Q1
$10.6M Sell
146,170
-7,150
-5% -$509K 0.19% 139
2014
Q4
$10.7M Sell
153,320
-9,260
-6% -$625K 0.19% 133
2014
Q3
$10.5M Sell
162,580
-10,290
-6% -$651K 0.19% 128
2014
Q2
$10.8M Sell
172,870
-4,300
-2% -$257K 0.2% 128
2014
Q1
$10.4M Sell
177,170
-35,857
-17% -$2M 0.19% 129
2013
Q4
$10.9M Sell
213,027
-72,710
-25% -$3.64M 0.2% 126
2013
Q3
$14.4M Sell
285,737
-46,903
-14% -$2.46M 0.27% 105
2013
Q2
$16.3M Buy
+332,640
New +$18.1M 0.32% 73

Other funds holding LLY

Nomura Asset Management's LLY Position: Q1 2026 in Review

Nomura Asset Management increased its Eli Lilly (LLY) stake by 3.1% in Q1 2026, buying an estimated $11.7M and bringing the position to 380,578 shares worth $350M. The position accounts for 0.9% of the portfolio, ranked #13.

Nomura Asset Management first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $397M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Nomura Asset Management held 380,578 shares of Eli Lilly worth $350M as of Q1 2026.
  • Nomura Asset Management bought 11,546 Eli Lilly shares in Q1 2026, an estimated $11.7M.
  • Eli Lilly made up 0.9% of Nomura Asset Management's portfolio in Q1 2026, its #13 holding.
  • Nomura Asset Management first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
  • Nomura Asset Management's Eli Lilly position peaked at $397M in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Nomura Asset Management's 13F filing for Q1 2026, filed 11 May 2026.